Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

International Murex Technologies (US) launches second-generation HCV test:

This article was originally published in Clinica

Executive Summary

International Murex Technologies (US) has introduced its second-generation HCV serotyping test - initially outside the US. The test has been approved for in vitro diagnostic use in France, Murex notes. The sale of the assay, which covers HCV types 1-6, is "not currently affected by injunctions blocking Murex from manufacturing and selling its anti-HCV screening test", the company says. There are approximately five million confirmed HCV-infected people in Europe, of which 3.4 million have chronic active hepatitis.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT094344

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel